GO:2000062 negative regulation of ureter smooth muscle cell differentiation

The Gene Ontology (GO) term GO:2000062, negative regulation of ureter smooth muscle cell differentiation, defines any process that stops, prevents, or reduces the frequency, rate or extent of ureter smooth muscle cell differentiation. This biological_process is critical for understanding how the embryonic ureter acquires its contractile machinery in a temporally controlled manner. Ureter smooth muscle differentiation is a late developmental event that begins after the ureteric bud has elongated and the surrounding mesenchyme has condensed. Proper timing of this differentiation is essential for the onset of peristaltic contractions that transport urine from the kidney to the bladder. Researchers study GO:2000062 to uncover the molecular brakes that prevent premature smooth muscle differentiation, which could otherwise disrupt ureter morphogenesis. The transcription factors TSHZ3 and SOX9 have been identified as negative regulators that reduce the activity of myocardin, a coactivator of serum response factor (SRF) that drives smooth muscle gene expression. By delaying differentiation, these factors ensure that the ureter reaches the appropriate length and diameter before contractile function begins. Understanding this process has clinical relevance because abnormal timing of smooth muscle differentiation is associated with congenital anomalies such as ureteropelvic junction obstruction and hydronephrosis [1,2]. This article synthesizes the current knowledge on GO:2000062, covering its definition, key genes, regulatory mechanisms, disease links, and experimental methods for studying it.

GO:2000062 is a Gene Ontology biological_process term that encompasses any molecular event or pathway that negatively regulates the differentiation of smooth muscle cells in the ureter. According to the QuickGO definition, it includes processes that stop, prevent, or reduce the frequency, rate, or extent of ureter smooth muscle cell differentiation. This term is a child of negative regulation of smooth muscle cell differentiation and is specific to the ureter, distinguishing it from negative regulation of smooth muscle differentiation in other organs such as the gut or vasculature. The term has no synonyms in QuickGO.

GO:2000062 is important because the timing of ureter smooth muscle differentiation is critical for establishing a functional urinary tract. Premature differentiation can lead to structural abnormalities, while delayed or failed differentiation results in impaired peristalsis and urine transport [1,2]. Understanding the negative regulators of this process provides insight into congenital urinary tract malformations and may inform regenerative strategies for ureteral tissue engineering.

The following genes and proteins are experimentally validated players in the negative regulation of ureter smooth muscle cell differentiation.

The negative regulation of ureter smooth muscle cell differentiation is itself subject to regulation by upstream signaling pathways. Sonic hedgehog (SHH) from the ureteric epithelium induces BMP4 in the surrounding mesenchyme, which in turn controls the expression of TSHZ3 and SOX9 [1,2]. The balance between pro-differentiation signals (e.g., myocardin-SRF) and anti-differentiation signals (e.g., TSHZ3, SOX9) determines the timing of differentiation. Additionally, mechanical forces from urine flow may modulate this process, although direct evidence is limited. Post-translational modifications of myocardin, such as phosphorylation, can also affect its activity and thus the rate of differentiation.

Congenital ureteropelvic junction obstruction (UPJO) is a common cause of hydronephrosis in children and is characterized by impaired urine flow from the renal pelvis to the ureter. Disruption of negative regulation of ureter smooth muscle differentiation can lead to premature and disorganized smooth muscle layers, contributing to UPJO. Mouse models with mutations in TSHZ3 or SOX9 exhibit UPJO-like phenotypes, including hydronephrosis and reduced peristalsis. These findings suggest that proper temporal control of smooth muscle differentiation is essential for a patent ureter [1,2].

Hydronephrosis, the swelling of the kidney due to urine buildup, can result from abnormal ureter smooth muscle differentiation. In mice, loss of negative regulation leads to excessive smooth muscle that narrows the ureter lumen, causing hydronephrosis. Human studies have linked mutations in genes involved in ureter development, such as TSHZ3, to urinary tract malformations. Understanding GO:2000062 may provide insights into the pathogenesis of these conditions.

The molecular players in GO:2000062, such as myocardin and SRF, are also involved in smooth muscle differentiation in other organs. Dysregulation of these factors has been implicated in vascular diseases, asthma, and gastrointestinal motility disorders. Therefore, insights from ureter smooth muscle differentiation may have broader implications for understanding smooth muscle pathology.

RNA sequencing (RNA-seq) of ureters at different embryonic stages can identify genes whose expression changes during smooth muscle differentiation. Comparing wild-type and TSHZ3 or SOX9 knockout ureters reveals differentially expressed genes and pathways. This approach has been used to show that TSHZ3 represses myocardin and other smooth muscle genes.

In situ hybridization and immunofluorescence can localize mRNA and protein expression of key regulators and differentiation markers in the developing ureter. For example, caveolin-3 immunostaining marks differentiated smooth muscle cells and can be used to assess the timing of differentiation in vivo. Co-staining for TSHZ3, SOX9, and myocardin can reveal spatial relationships.

ChIP assays can determine whether TSHZ3 or SOX9 directly bind to the myocardin promoter or other regulatory regions. Luciferase reporter assays using the myocardin promoter can test the repressive activity of these factors. These methods provide mechanistic insights into negative regulation.

Ureter explant culture allows manipulation of gene expression using siRNAs, overexpression plasmids, or pharmacological inhibitors, followed by assessment of smooth muscle differentiation markers and peristaltic contractions [1,2]. This method bridges in vitro molecular findings with tissue-level function.

Researchers studying negative regulation of ureter smooth muscle cell differentiation-related genes often need to determine whether a candidate gene is causally involved in the timing of differentiation or is merely a bystander. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell and animal models, enabling rigorous functional validation of genes in GO:2000062.

GO:2000062, negative regulation of ureter smooth muscle cell differentiation, is a critical biological process that ensures proper timing of smooth muscle development in the urinary tract. The transcription factors TSHZ3 and SOX9 act as molecular brakes by reducing myocardin activity, thereby preventing premature differentiation. Disruption of this regulation leads to congenital anomalies such as ureteropelvic junction obstruction and hydronephrosis [1,2]. Continued research using CRISPR-based models and advanced omics will further elucidate the mechanisms and therapeutic potential of targeting this pathway.